Diabetes Drug Invokana Is J&J’s Cure for Subpar Performance
Rarely far from the pharmaceutical headlines, Johnson & Johnson (J&J) have big plans for popular diabetes drug Invokana in 2017. Following disappointing revenue results reported earlier this week, the company's drugs and medical devices profits in Q4 2016 have been…